Inovio Pharmaceuticals, Inc. (INO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Company Overview - Inovio Pharmaceuticals is a clinical-stage biotech company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases [2] - The company has recently had its Biologics License Application (BLA) for its lead program, INO-3107, accepted for review by the FDA, marking a significant milestone [2] Product Pipeline - INO-3107 is a potential treatment for recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV types 6 and 11 [2] - The FDA accepted the BLA under the accelerated approval program and granted a standard review, indicating a positive regulatory outlook for the product [2]